Stocksigma LogoStocksigma Logo

Astonea Labs Reports Nil Deviation in IPO Proceeds Utilisation for Sep'26 Half-Year

Astonea Labs Limited reported nil deviation or variation in the utilisation of its IPO proceeds for the half year ended 30th Sep'26 under Regulation 32 of

Astonea Labs Reports Nil Deviation in IPO Proceeds Utilisation for Sep'26 Half-Year

Astonea Labs Ltd 路 Others (Uncategorized) 路 15 Nov 2026, 2:16 am

Astonea Labs Reports Nil Deviation in IPO Proceeds Utilisation for Sep'26 Half-Year Astonea Labs Limited reported nil deviation or variation in the utilisation of its IPO proceeds for the half year ended 30th Sep'26 under Regulation 32 of SEBI LODR. Out of total funds raised amounting to Rs 37.67 cr through the issuance of 27.90 lakh equity shares, the company utilised Rs 36.43 cr across key objectives, including working capital (Rs 19.75 cr) and equity investment in Damaira Pharmaceuticals (Rs 6.25 cr). The unutilised balance stands at Rs 1.23 cr as of 30th Sep'26.

Original exchange filing (PDF)

More announcements from Astonea Labs Ltd

All Astonea Labs Ltd announcements